Not Yet RecruitingNCT07011953
This study is comparing Antipsychotics plus Levothyroxine Sodium with placebo for people with Schizophrenia or Avolition. Participants receive Antipsychotics plus Levothyroxine Sodium or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 45 Years
- Countries
- Global
- Sponsor
- Peking University
- Condition
- Schizophrenia
RecruitingNCT06961916
This study is looking at whether Active rTMS can help people with Schizophrenia. Participants take part in Active rTMS and complete follow-up assessments.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
- Condition
- Schizophrenia
RecruitingNCT04366518
This study is comparing Rivastigmine Transdermal System with placebo for people with Hallucinations, Auditory or Psychosis. Participants receive Rivastigmine Transdermal System or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- United States
- Sponsor
- Yale University
- Condition
- Schizophrenia
RecruitingNCT06888726
This study is comparing High-intensity transcranial alternating current stimulation (Hi-tACS) with control group for people with Schizophrenia, Negative Type, or Transcranial Alternating Current Stimulation. Participants receive High-intensity transcranial alternating current stimulation (Hi-tACS) or control group and complete study visits and assessments.
SchizophreniaOtherOver 18 Years
- Countries
- China
- Sponsor
- Shanghai Mental Health Center
- Condition
- Schizophrenia
RecruitingNCT07001878
This observational study is following people with Psychosis or Cannabis Use to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
SchizophreniaOtherFrom 18 Years to 25 Years
- Countries
- Canada
- Sponsor
- Nova Scotia Health Authority
- Condition
- Schizophrenia
RecruitingNCT03781115
This study is comparing Ziprasidone with placebo for people with Schizophrenia. Participants receive Ziprasidone or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 18 Years to 40 Years
- Countries
- United States
- Sponsor
- University of Arizona
- Condition
- Schizophrenia
Not Yet RecruitingNCT06975670
This study is looking at whether a digital support tool can help people with Psychosis. Participants take part in the program and complete follow-up questionnaires or assessments.
SchizophreniaOtherFrom 18 Years to 60 Years
- Countries
- Global
- Sponsor
- Makerere University
- Condition
- Schizophrenia
RecruitingNCT06126224
This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 90 Years
- Countries
- Belgium, Canada, Chile, China, Greece, Hungary, Mexico, Peru, Poland, South Korea, Switzerland, Turkey, United Kingdom, United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
Enrolling By InvitationNCT07095465
This study is looking at care and outcomes for people with Lewy Body Dementia Psychosis. Taking part may give some people access to ACP-204, but direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 84 Years
- Countries
- Czech Republic, United States
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
RecruitingNCT05980949
This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Taking part may give some people access to KarXT, but direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 90 Years
- Countries
- Argentina, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Peru, Poland, Portugal, United States, Romania, Serbia, Slovakia, South Korea, Spain, Turkey, Ukraine, United Kingdom
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT07029581
This study is looking at care and outcomes for people with Lewy Body Dementia Psychosis. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 84 Years
- Countries
- Bulgaria, Czech Republic, France, Italy, Serbia, United States
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
RecruitingNCT05511363
This study is looking at care and outcomes for people with Psychosis Associated With Alzheimer's Disease. Some participants may receive placebo instead of the study treatment, and direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 90 Years
- Countries
- Bulgaria, Croatia, Czech Republic, France, Germany, Italy, Serbia, Slovakia, Spain, United Kingdom, United States
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Condition
- Schizophrenia
RecruitingNCT07226895
This study is comparing MT1988 Low Dose with placebo for people with Clinical High Risk for Psychosis. Participants receive MT1988 Low Dose or placebo and complete study visits and assessments.
SchizophreniaOtherFrom 17 Years to 30 Years
- Countries
- United States
- Sponsor
- Monument Therapeutics Limited
- Condition
- Schizophrenia
RecruitingNCT06159673
This observational study is following people with Alzheimer's Disease Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 55 Years to 95 Years
- Countries
- Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
Active Not RecruitingNCT05310838
This study is looking at whether Behavioral Activation for First Episode Psychosis can help people with Engagement or First Episode Psychosis. Participants receive Behavioral Activation for First Episode Psychosis or usual care and complete study visits and assessments.
SchizophreniaOtherFrom 15 Years to 35 Years
- Countries
- United States
- Sponsor
- California State University, San Bernardino
- Condition
- Schizophrenia
Not Yet RecruitingNCT07471334
This observational study is following people with Focal Epilepsy With and Without Secondary Generalization or Psychotic Symptoms to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
SchizophreniaOtherOver 18 Years
- Countries
- Global
- Sponsor
- Central Hospital, Nancy, France
- Condition
- Schizophrenia
RecruitingNCT07459244
This observational study is following people with Methamphetamine Use Disorder or Methamphetamine Induced Psychosis to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Turkey
- Sponsor
- Elazığ Mental Health and Diseases Hospital
- Condition
- Schizophrenia
Not Yet RecruitingNCT07459270
This observational study is following people with Methamphetamine Induced Psychosis or Cannabis Use to understand outcomes over time. Participants are followed over time so researchers can learn from clinical and follow-up information.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Turkey
- Sponsor
- Elazığ Mental Health and Diseases Hospital
- Condition
- Schizophrenia
RecruitingNCT07459257
This observational study is following people with Methamphetamine Induced Psychosis to understand outcomes over time. Participants mainly provide questionnaire, assessment, or follow-up information rather than receiving a new study treatment.
SchizophreniaOtherFrom 18 Years to 65 Years
- Countries
- Turkey
- Sponsor
- Elazığ Mental Health and Diseases Hospital
- Condition
- Schizophrenia
Enrolling By InvitationNCT06194799
This study is looking at care and outcomes for people with Alzheimer's Disease Psychosis. Taking part may give some people access to ACP-204, but direct benefit is not guaranteed.
SchizophreniaOtherFrom 55 Years to 95 Years
- Countries
- Brazil, Bulgaria, Chile, Czech Republic, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan, United States
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Condition
- Schizophrenia
Active Not RecruitingNCT05967195
This study is looking at whether Financial Incentive and Text-Messages can help people with First-Episode Psychosis. Participants take part in Financial Incentive and Text-Messages and complete follow-up assessments.
SchizophreniaOtherOver 18 Years
- Countries
- United States
- Sponsor
- University of Pennsylvania
- Condition
- Schizophrenia
RecruitingNCT05398120
This study is looking at whether cognitive behavioural therapy can help people with Clinical High-Risk or Psychological. Participants take part in the program and complete follow-up questionnaires or assessments.
SchizophreniaOtherFrom 13 Years to 18 Years
- Countries
- United States
- Sponsor
- University of Pittsburgh
- Condition
- Schizophrenia
Not Yet RecruitingNCT07387705
This study is looking at whether On Track for Wellness can help people with Sleep, Physical Activity, or First Episode Psychosis. Participants receive advice and support from a mental health professional about oral health and daily oral hygiene.
SchizophreniaOther
- Countries
- Global
- Sponsor
- University of Illinois at Chicago
- Condition
- Schizophrenia
RecruitingNCT05968560
This study is looking at evaluate the feasibility and effectiveness of telehealth interventions for individuals at clinical high risk for psychosis (CHR). Participants take part in the program and complete follow-up questionnaires or assessments.
SchizophreniaOtherFrom 14 Years to 25 Years
- Countries
- United States
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Condition
- Schizophrenia
RecruitingNCT06540833
This study is comparing ITI-1284 with placebo for people with Psychosis Associated With Alzheimer's Disease. Participants receive ITI-1284 or placebo and complete study visits and assessments.
SchizophreniaOtherOver 55 Years
- Countries
- Bulgaria, Croatia, Czech Republic, Poland, Romania, Serbia, Slovakia, Spain, United States
- Sponsor
- Intra-Cellular Therapies, Inc.
- Condition
- Schizophrenia